Drug Trial Radar · NCT01026064
Cantharidin-induced Skin Blister for Testing Anti-inflammatory Effects of Macrolides
Last checked: Nov 19, 2026Latest source record: Jul 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Jun 4, 2009
Primary completion
Nov 27, 2009
Study completion Nov 27, 2009
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Dec 4, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the utility of the cantharidin-induced skin blister assay for evaluation of the anti-inflammatory effects of macrolides in healthy male volunteers.
Conditions
- Inflammation
Interventions
CantharidinOther
Cantharone topical liquid containing 0.7% cantharidin (blistering agent) is applied as 25 µL of 0.1% cantharone solution in acetone
AzithromycinDrug
Zithromax (250 mg oral capsule).
PlaceboDrug
Matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tolerability and safety of cantharidin-induced skin blister assay (as determined by AEs, pain intensity, systemic inflammatory response, healing time, and cosmetic appearance of blister area)Time frame: Study duration
- Total cell count, neutrophil count and monocyte/macrophage count in blister fluid.Time frame: Part C: end of treatment and potentially 3 weeks later
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Cambridge, Cambridgeshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.